linagliptin
Trajenta · ATC code A10BH05
Brand names: Trajenta, Ilinpru, Liamell, Linacon, Neripar, Sansik, Linagliptin Abdi, Atalyna, Dialipta, Dianovia, Elnaglip, Linadiya, Linatin, Linazep, Lincretin …
- Key facts
- Active substance
- linagliptin
- Drug class
- Dipeptidyl peptidase-4 inhibitors
- ATC code
- A10BH05
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Trajenta 5 mg film-coated tablets
- Marketing authorisation holder
- Boehringer Ingelheim International GmbH
- Information as of
- 2026-10-27
Key facts
Linagliptin is a DPP-4 inhibitor that lowers blood glucose. It is used in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
What it is used for
- Monotherapy in adults with type 2 diabetes when metformin is inappropriate due to intolerance or contraindicated due to renal impairment
- Combination therapy with other diabetes medicines, including insulin, when these do not provide adequate glycaemic control
Dosing
- 5 mg once daily, with or without a meal at any time of day
- When added to metformin, the metformin dose is maintained
- With a sulphonylurea or insulin, a lower dose of these may be considered to reduce hypoglycaemia risk
- No dose adjustment for renal impairment, hepatic impairment (limited experience) or age
- Not recommended in children and adolescents
- A missed dose is taken when remembered, but not a double dose on the same day
Contraindications
- Hypersensitivity to the active substance or any of the excipients
Important warnings
- Not for type 1 diabetes or diabetic ketoacidosis
- Hypoglycaemia: caution in combination with a sulphonylurea and/or insulin
- Acute pancreatitis has been observed (CARMELINA: 0.3% on linagliptin vs 0.1% on placebo)
- Bullous pemphigoid (CARMELINA: 0.2%); discontinue if suspected
Side effects
- Most frequent: hypoglycaemia under triple combination with metformin and a sulphonylurea (14.8% vs 7.6% on placebo)
- Overall incidence of adverse events similar to placebo
- Serious: pancreatitis, bullous pemphigoid
Interactions
- Rifampicin decreases linagliptin AUC and Cmax; full efficacy may not be achieved with strong P-gp inducers
- Sulphonylureas and insulin increase the risk of hypoglycaemia
- Overall low risk of clinically meaningful interactions
Pregnancy and breastfeeding
- Pregnancy: not studied; as a precaution, preferable to avoid
- Breast-feeding: excreted in milk in animals; a risk to the breast-fed child cannot be excluded
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- TrajentaBoehringer Ingelheim International GmbH · EMEA/H/C/002110
Source: European Medicines Agency (EMA), product information
Austria
- IlinpruViatris Limited · 1 register entry
- LiamellG.L. Pharma Gmbh · 1 register entry
- LinaconGenericon Pharma Gesellschaft M.B.H. · 1 register entry
- LinagliptinStada Arzneimittel Gmbh, 1a Pharma Gmbh, Ratiopharm Arzneimittel Vertriebs-Gmbh, Galenicum Health, S.L., +pharma Arzneimittel Gmbh, Accord Healthcare B.V., Sandoz Gmbh, Hcs Bvba · 8 register entries
- NeriparPharmapath Sa · 1 register entry
- SansikZentiva, K.S. · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Germany
- Linagliptin AbdiAbdi Farma Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- AtalynaATABAY KİMYA SAN. VE TİC. A.Ş. · 1 register entry
- DialiptaALİ RAİF İLAÇ SAN. A.Ş. · 1 register entry
- DianoviaBİOFARMA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- ElnaglipSABA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- LinadiyaBERKO İLAÇ VE KİMYA SAN. A.Ş. · 1 register entry
- LinatinNOBEL İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- LinazepBİLİM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- LincretinEİP ECZACIBAŞI İLAÇ PAZARLAMA A.Ş · 1 register entry
- LinigaGENVEON İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- LintrejaSANDOZ İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- LizeraABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- SnoxxSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
Show all 13 brand names
- TrajentaBOEHRİNGER INGELHEİM İLAÇ TİC. A.Ş. · 3 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 27 more European countries
- Belgium
- Linagliptin Eg, Linagliptin Sandoz, Linagliptine Eg, Linagliptine Hcs
- Bulgaria
- Linagliptin Accord, Глунава, Зифокам, Ларида, Линаглиптин Виатрис, Линаптин Нобел Фарма, Линатра, Линксарам
- Croatia
- Larida, Liglinra, Linagliptin Teva, Lynxaram, Sansik, Tingapla, Zyfoqam
- Cyprus
- Glunava, Linagliptin Accord, Linagliptin Krka, Linagliptin Pharmazac, Tingapla
- Czechia
- Glunava, Jeligo, Liamell, Linagliptin Abdi, Linagliptin Accord, Linagliptin Olpha, Linagliptin Sandoz, Linagliptin Stada, Linagliptin Teva, Linagliptin Viatris, Linagliptin Zentiva, Lynxaram, Pligant, Rekiva, Sansik, Zyfoqam
- Denmark
- Linagliptin "pharmapath", Linagliptin Accord, Linagliptin Krka, Linagliptin Sandoz, Linagliptin Stada, Linagliptin Teva, Linagliptin Viatris, Linagliptin Vivanta, Linathan, Neloviren, Nezodia
- Estonia
- Glunava, Linagliptin Accord, Linagliptin Olpha, Linagliptin Pharmazac, Lynxaram, Rekiva, Sansik, Tingapla
- Finland
- Linagliptin Accord, Linagliptin Advanz Pharma, Linagliptin Galenicum, Linagliptin Krka, Linagliptin Orion, Linagliptin Ratiopharm, Linagliptin Sandoz, Linagliptin Stada, Linagliptin Viatris
- Greece
- Bottiar, Drojarto, Glunava, Liglinra, Linagliptin Accord, Linagliptin Galenicum, Linagliptin Intas, Linagliptin Pharmazac, Linaglut, Lynxaram, Nezodia, Tingapla, Zyfoqam
- Hungary
- Aglocafor, Ilinpru, Jeligo, Linagliptin, Linagliptin/Metformin Hcl Pharos, Lynxaram, Sansik, Tingapla
- Iceland
- Linagliptin Krka, Linagliptin Stada, Trajenta
- Ireland
- Linagliptin Accord, Linagliptin Clonmel, Linagliptin Krka, Linagliptin Rowex, Linagliptin Teva, Linagliptin Viatris, Linagliptin Vivanta
- Italy
- Linagliptin Abdi, Linagliptin Aurobindo, Linagliptin Doc, Linagliptin Eg, Linagliptin Krka, Linagliptin Macleods, Linagliptin Mylan, Linagliptin Pensa, Linagliptin Sandoz, Linagliptin Vivanta, Linagliptin Zentiva, Ryoxana, Zireva
- Latvia
- Linagliptin Accord, Linagliptin Olpha, Linagliptin Pharmazac, Lynxaram, Sansik, Tingapla
- Liechtenstein
- Trajenta
- Lithuania
- Bottiar, Jeligo, Linagliptin Medochemie, Linagliptin Olpha, Linagliptin Pharmazac, Lynxaram, Tingapla
- Luxembourg
- Linagliptin Eg
- Malta
- Essemdon, Liamell, Linagliptin, Linathan
- Netherlands
- Linagliptin Viatris, Linagliptin Vivanta, Linagliptine Abdi, Linagliptine Accord, Linagliptine Aurobindo, Linagliptine Hcs, Linagliptine Intas, Linagliptine Macleods, Linagliptine Sandoz, Linagliptine Teva
- Norway
- Linagliptin Accord, Linagliptin Krka, Linagliptin Orion, Linagliptin Sandoz, Linagliptin Teva, Linagliptin Viatris, Linagliptin Vivanta, Trajenta
- Poland
- Jeligo, Larida, Liamell, Liglinra, Linagliptin Accord, Linagliptin Olpha, Linagliptin Tzf, Linatra, Lynxaram, Pligant, Rekiva, Sansik, Tingapla, Zyfoqam
- Portugal
- Enanta, Larida, Liglip, Linagliptina Alter, Linagliptina Anova, Linagliptina Bluepharma, Linagliptina Farmoz, Linagliptina Generis, Linagliptina Ipca, Linagliptina Kern Pharma, Linagliptina Krka, Linagliptina Omnicals, Linagliptina Pentafarma, Linagliptina Sandoz, Linagliptina Stada, Linagliptina Tad, Linagliptina Teva, Linagliptina Tolife, Linagliptina Viatris, Linagliptina Zentiva
- Romania
- Jeligo, Linagliptin Medochemie
- Slovakia
- Glunava, Ilinpru, Jeligo, Liamell, Lidagliptin Stada, Linagliptin Olpha, Linagliptin Stada, Linagliptin Teva, Linagliptin Viatris, Lynxaram, Pligant, Sansik, Zyfoqam
- Slovenia
- Liglipex, Linagliptin Krka, Linagliptin Stada Arzneimittel Ag, Linagliptin Vivanta, Lynxaram, Zyfoqam
- Spain
- Donumid, Ilinpru, Linagliptin Vivanta, Linagliptina Alter, Linagliptina Aurovitas, Linagliptina Cinfa, Linagliptina Combix, Linagliptina Dr. Reddys, Linagliptina Intas, Linagliptina Kern Pharma, Linagliptina Krka, Linagliptina Macleods, Linagliptina Medochemie, Linagliptina Novumgen, Linagliptina Olpha, Linagliptina Pensa, Linagliptina Sandoz, Linagliptina Stada, Linagliptina Viatris
- Sweden
- Liglinra, Linagliptin Accord, Linagliptin Advanz Pharma, Linagliptin Demo S.A., Linagliptin Krka, Linagliptin Orion, Linagliptin Pharmazac, Linagliptin Sandoz, Linagliptin Stada, Linagliptin Teva, Linagliptin Viatris, Linagliptin Vivanta, Linagliptin Zentiva, Zyfoqam
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Trajenta – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/trajenta-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC A10BH.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.